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Efficient viral delivery of Cas9 
into human safe harbor
Hideki Hayashi1*, Yoshinao Kubo2, Mai Izumida2 & Toshifumi Matsuyama3
Gene editing using CRISPR/Cas9 is a promising method to cure many human genetic diseases. We 
have developed an efficient system to deliver Cas9 into the adeno-associated virus integration site 1 
(AAVS1) locus, known as a safe harbor, using lentivirus and AAV viral vectors, as a step toward future 
in vivo transduction. First, we introduced Cas9v1 (derived from Streptococcus pyogenes) at random 
into the genome using a lentiviral vector. Cas9v1 activity was used when the N-terminal 1.9 kb, and 
C-terminal 2.3 kb fragments of another Cas9v2 (human codon-optimized) were employed sequentially 
with specific single-guide RNAs (sgRNAs) and homology donors carried by AAV vectors into the 
AAVS1 locus. Then, Cas9v1 was removed from the genome by another AAV vector containing sgRNA 
targeting the long terminal repeat of the lentivirus vector. The reconstituted Cas9v2 in the AAVS1 
locus was functional and gene editing was efficient.
The clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system is widely used for genome 
 editing1,2. Introduction of inducible Cas9 into the adeno-associated virus integration site 1 (AAVS1) locus in 
human stem cell lines, ex vivo, provides a platform for subsequent gene  editing3,4. The AAVS1 locus, in intron 1 
of PPP1R12C (protein phosphatase 1 regulatory subunit 12C), is known as a “safe harbor” because its disruption 
does not have adverse effects on the cell, and robust transcription can be used to maintain the expression of an 
exogenously inserted  gene5–7. For precise gene editing using homology-directed repair (HDR), the Cas9 gene, 
single-guide RNA (sgRNA), and homology arms must be introduced. Cas9 delivery is usually performed using 
transfection or electroporation, in vitro, as it is too large to pack into an adeno-associated virus (AAV) vector 
bundled with homology  arms8,9. To solve this problem, SaCas9 from Staphylococcus aureus, which is smaller than 
SpCas9, was used to package the AAV  vector10. Previous studies have reported the expression of Cas9 N- and 
C-terminal segments in different vectors, followed by reconstitution using either intein-mediated trans-splicing 
or a photo-inducible dimerization  system11,12. Non-integrating lentiviral or adenovirus vectors have also been 
used for Cas9  delivery13,14. Here, we propose a new method, using only viral vectors, to efficiently integrate Cas9 
into the AAVS1 locus by exploiting the advantages of lentiviral and AAV vectors for future in vivo applications. 
Both specific sgRNA and homologous arms are small enough to be packed into an AAV vector, which is consid-
ered the safest viral vector for use in vivo15. If Cas9 is integrated into the AAVS1 locus of target cells, its stable 
expression will efficiently enable precise gene editing. The AAVS1 site-integrated Cas9 was also used for the 
effective removal of the lentivirus containing Cas9 integrated into the genome at  random16,17. Given the capacity 
of the AAV vector between inverted terminal repeats (ITRs) of ~ 4.7 kb, the actual size of the introducing gene 
is limited to approximately 2.5 kb. For precise gene editing using HDR, the vector needs to carry an additional 
1.9–2.2 kb [0.4 kb for sgRNA with U6 promoter, 0.6 kb for left and right homology arms, 0.7 kb or 0.4 kb for 
puromycin or blasticidin resistance gene with a 0.3 kb polyadenylation signal, and small connecting fragments 
such as targeting sites, splice acceptor, T2A (Thosea asigna virus 2A), and P2A (porcine teschovirus-1 2A) self-
cleaving peptides]. Therefore, we have to introduce the Cas9 N- and C-terminal halves sequentially. Here, we 
present a basic four-step strategy to efficiently introduce Cas9 into the AAVS1 locus, followed by a modified 
protocol to reduce off-target effects. The modified protocol could be further improved by employing both the 
modified Cas9s to minimize off-target effects and using non-integrating lentivirus to reduce the genetic  risk13,18.
Results
Integration of wild-type Cas9 into the AAVS1 locus. We developed a method to integrate Cas9 into 
the AAVS1 locus using only viral vectors; thus, exploiting the advantages of both lentiviral and AAV vectors. Sta-
bly expressed Cas9 enables precise gene editing after transduction with AAV vectors containing specific sgRNAs 
and homologous arms, thus enabling  HDR15. As shown in Fig. 1, we used two types of Cas9: Cas9v1, original 
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SpCas9 (Streptococcus pyogenes), and Cas9v2, human codon-optimized from  SpCas919. Although they encode 
for the same protein, Cas9 differs in its DNA sequence, enabling sgRNA2 in AAV vector #2 to recognize Cas9v2, 
but not Cas9v1. To monitor the expression of both Cas9s at the protein level, we added Myc-tag and FLAG-tag 
to Cas9v1 and Cas9v2, respectively (Fig. 1). In addition, we employed a double-cut donor method, with 0.3 kb 
short homology arms, to enable HDR and minimize the size of insertion DNA for AAV  vectors20,21. The pro-
cedure comprised the following four steps: (1) Cas9v1 (S. pyogenes derived) was randomly introduced into the 
genome of host cells using a lentiviral vector; this could accommodate the large size of Cas9v1, and ensure its 
robust and stable expression, though the integration site was uncontrolled; (2) Cas9v1 nuclease activity was used 
to introduce the 1.9 kb Cas9v2 N-terminal fragment (human codon-optimized) into the AAVS1 locus via the 
AAV vector #1, as its exogenous gene capacity was ~ 2.5 kb (~ 2.2 kb is used for sgRNA, homology arms, con-
necting peptides, a puromycin resistant gene and polyadenylation signal); (3) full-length Cas9v2 was reconsti-
tuted in the AAVS1 locus using HDR, with the AAV vector #2 providing the 2.3 kb Cas9v2 C-terminal fragment, 
as well as a 0.3 kb region overlapping the 1.9 kb N-terminal fragment; (4) lentivirus, containing Cas9v1, was 
removed from the genome using the AAV vector #3, which contained sgRNA targeting long terminal repeats 
(LTR) in the lentiviral vector.
(1) Random integration of Cas9v1-Myc into the genome
First, we introduced Cas9v1-Myc into the host genome of human embryonic kidney (HEK) 293 T cells by random 
integration using a lentiviral vector. For robust and ubiquitous expression in many cells, both the Cas9v1-Myc 
transcript and the hygromycin resistance gene, connected with a T2A self-cleaving peptide, were driven via a 
cytomegalovirus (CMV) promoter. Transduced HEK293T cells were selected with hygromycin B for two weeks. 
All five hygromycin-resistant clones (100%) expressed Cas9v1-Myc (Supplementary Fig S1).
Figure 1.  Schematic diagram of the four-step integration strategy of Cas9 into the AAVS1 locus. (1) The first 
step is to generate a cell line expressing Cas9v1 by random integration of the recombinant lentivirus in the host 
genome. (2) Using the Cas9v1 nuclease activity, the N-terminal 1.9 kb fragment of Cas9v2 was introduced into 
the AAVS1 locus by AAV vector #1 with the sgRNA1-targeting AAVS1 site and the homology arms flanking 
the Cas9 N-terminal 1.9 kb fragment. (3) full-length Cas9v2 was reconstituted in the AAVS1 locus using HDR, 
with AAV vector #2 providing the 2.3 kb Cas9v2 C-terminal fragment, as well as a 0.3 kb region overlapping 
the 1.9 kb N-terminal fragment; (4) lentivirus, containing Cas9v1, was removed from the genome using AAV 
vector #3, which contained sgRNA targeting long terminal repeats (LTR) in the lentiviral vector. The schematic 
structures of wild-type Cas9v2, Cas9v2 nickase (Cas9nikase), and dead Cas9v2 (dCas9) made by the same 
procedures as wild-type Cas9v2 are shown in brackets. The sgRNAs targeting AAVS1, the 3′-end of the Cas9v1 
N-terminal 1.9 kb fragment and the LTR of the lentivirus are shown as sg1, sg2, and sg3, respectively. AAVS1, 
adeno-associated virus integration site 1 (intron1 of the PPP1R12C, protein phosphatase 1 regulatory subunit 
12C); EX, exon; Cas9v1, S. pyogenes-derived Cas9; Cas9v2, human codon-optimized Cas9; VP64, Herpes 
simplex virus transcriptional activator domain (TA).
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(2) Integration of the 1.9 kb Cas9v2 N-terminal fragment into the AAVS1 locus
Using Cas9v1-Myc nuclease activity, a 1.9 kb Cas9v2 N-terminal fragment was introduced into the AAVS1 locus 
using an AAV vector (Fig. 2). To enable HDR, AAV vector #1 was designed to express AAVS1-specific sgRNA1 
(sg1), and to provide both a double-cut donor, with 0.3 kb short homology arms, and T1 targeting sequences, 
including a protospacer adjacent motif (PAM)20,21. The complete sequence of AAV #1 is shown in Supplemen-
tary Table S1. When HDR occurs, both the 1.9 kb Cas9v2 N-terminal and the puromycin resistance gene are 
expressed from the robust PPP1R12C transcript, via a splice acceptor (SA), T2A, and P2A self-cleaving peptides. 
HEK293T cells expressing Cas9v1-Myc (clone #2) were transduced with the AAV vector #1 and then selected 
for 2 weeks using puromycin. Genomic DNA, prepared from puromycin-resistant cells (clones #1–#15), was 
analyzed using PCR, with primers P1–P2 set outside the homology arms (Fig. 3A). Primer sequences are listed 
in Supplementary Table S3. The 4.5 kb and 1.5 kb PCR products were from the N-terminal of integrated Cas9v2 
and nonintegrated original alleles, respectively. Eight of the 15 clones examined (53%) had two bands, indicat-
ing that only one allele had N-terminal Cas9v2, while only the clone #8 had inserts (4.5 kb and 4.2 kb) in both 
alleles. Possible Cas9v2-integrated clones (PCR 4.5 kb product) were further analyzed using primers P1–P3 and 
P4–P2. All eight candidates had the Cas9v2 gene (Fig. 3B: 1.2 kb using primers P1–P3) and puromycin (Fig. 3C: 
1.1 kb using primers P4–P2). In addition, following 6% SDS-PAGE, lysates obtained from the cells used for PCR 
analysis were analyzed using immunoblot with an antibody recognizing both Cas9s. All eight clones expressed 
the 1.9 kb N-terminal of Cas9v2 (70 kDa) as well as Cas9v1-Myc (160 kDa) (Fig. 3D). The 4.5 kb sequence of 
the N-terminal (NT) clone #4 fragment was determined by Sanger sequencing and confirmed the gene structure 
outlined in Fig. 2B. The DNA sequence of clone #4 is listed in Table S2. The 4.5 kb fragment from clone #8 was 
the same as that of clone #4; however, the 4.2 kb fragment from clone #8 possessed both an insertion and dele-
tion around the right homology arm (Supplementary Fig S2).
(3) Reconstitution of full-length Cas9v2-FLAG at the AAVS1 locus
To reconstitute full-length Cas9v2-FLAG using HDR, we introduced a 2.6 kb fragment containing the 2.3 kb 
C-terminal (CT) fragment of Cas9v2-FLAG and the 0.3 kb region overlapping the 1.9 kb N-terminal fragment, 
Figure 2.  AAV vector #1 construct for introduction of N-terminal 1.9 kb Cas9v2 into the AAVS1 locus. (A) 
AAV vector #1 is designed to introduce the N-terminal Cas9v2 into the AAVS1 locus as a double-cut donor. 
The vector sequence is shown in Supplementary Table S1. T1 is the AAVS1 target site including the protospacer 
adjacent motif (PAM). The T1 sequence was synthesized and added adjacent to each homology arm to cut out 
the donor DNA from the AAV vector genome. U6, U6 RNA polymerase III promoter; sg1, AAVS1-specific 
sgRNA1; LA and RA, left and right homology arms; SA, splicing acceptor; T2A and P2A: Thosea asigna virus 
and porcine teschovirus-1 2A self-cleaving peptides; Puro, puromycin resistance gene; pA, a polyadenylation 
signal sequence; ITR, inverted terminal repeat. (B) Genome structure after integration of the donor by 
HDR. Primers P1–P2 for PCR were placed outside of the homology arms. Primers P1–P3 and P4–P2 were 
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via the AAV vector #2 (Fig. 4). sgRNA2 (sg2) targets the junction sequence (T2) between the 3′-end of the 
1.9 kb N-terminal Cas9v2 and the 5′-end of the P2A self-cleaving peptide. P2A, and the 0.3 kb N-terminal 
fragment of puromycin, were used as the right homology arm; to provide a double-cut donor, the fragment 
flanked the T2 target sequence and ITR (Supplementary Table S1). P2A expresses a blasticidin resistance gene 
as well as reconstituted full-length Cas9v2-FLAG, from the PPP1R12C promoter-driven transcript present at 
the AAVS1 site. The puromycin-resistant gene was also reconstituted using HDR; however, it was not translated 
to protein due to the stop codon following the blasticidin resistance gene. The AAV vector #2 was introduced 
into HEK293T cells expressing both Cas9v1-Myc and the 1.9 kb N-terminal of Cas9v2 (NT clone #4); they were 
then selected with blasticidin for 2 weeks. Blasticidin-resistant cells (clones #1–#9) were sensitive to puromycin, 
and their genomic DNA was prepared and analyzed using PCR, with primers P5–P6 (Fig. 5A). Donor element 
integration was indicated by 1.2 kb PCR products detected in all nine clones. Following 6% SDS-PAGE, lysates 
from the same cells were analyzed by immunoblotting with an antibody recognizing both Cas9s (Fig. 5B). In all 
the AAV vector #2-transduced cells, the 70 kDa band, indicating the 1.9 kb N-terminal of Cas9v2, disappeared, 
while 160 kDa bands increased in intensity. These bands were confirmed to have reconstituted full-length Cas9v2-
FLAG and Cas9v1-Myc with anti-FLAG (Fig. 5C) and anti-Myc antibodies (Fig. 5D), respectively. The sequence 
of Cas9v2 full-length clone #7, including the AAVS1 integration site, was confirmed via Sanger sequencing 
(Supplementary Table S2).
(4) Removal of randomly integrated lentivirus, containing Cas9v1-Myc, from the genome
To remove randomly integrated lentivirus, containing Cas9v1-Myc, from the genome, we constructed the 
AAV vector #3, which used non-homologous end joining (NHEJ) to target the LTR of the lentiviral vector 
(T3) (Fig. 6A,B). To select cells expressing sgRNA, we used a puromycin resistance gene, as cells expressing 
Figure 3.  PCR and immunoblot to confirm N-terminal Cas9v2 genomic integration and expression. (A) 
Genomic DNA from parent HEK293T-Cas9v1-Myc cells (Cas9v1#2) and the 293 T-Cas9v1-Myc cells expressing 
the 1.9 kb N-terminal Cas9v2 after AAV vector #1 infection and puromycin selection (+ v2-NT #1–#15) was 
analyzed by PCR with primers P1–P2 (4-min extension at 68 °C). The 4.5 kb and 1.5 kb PCR products are from 
the N-terminal Cas9v2-integrated and non-integrated original alleles, respectively. The Cas9v2 NT #8 clone 
had 4.5 kb and 4.2 kb PCR products. (B) Further analysis of the Cas9v2-integrated clones with primers P1–P3 
(1.2 kb for Cas9v2). (C) Further analysis of the Cas9v2-integrated clones with primers P4–P2 (1.1 kb for Puro). 
D. The lysates obtained from the cells used for (B,C) were analyzed by immunoblot using an antibody against 
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Cas9v1-Myc and full-length Cas9v2-FLAG lost functional puromycin expression (Fig. 4B). Previous reports 
indicate that sgRNA targeting LTR of HIV successfully removed genes between the LTR in many  cases16,17. We 
set a pair of sgRNAs (sg3-1 and sg3-2), with a 16 bp offset, for a DNA double-strand break (DSB) using Cas9 
nickase as well as wild-type Cas9 (Fig. 6A). Nickase requires a pair of offset (usually − 4 to 20 bp) sgRNAs, 
complementary to the opposite strand of the target  site22,23. HEK293T cells expressing both Cas9v1-Myc and 
full-length Cas9v2-FLAG (Cas9v2 full-length clone #7) were transduced with the AAV vector #3 and then 
selected with puromycin. Puromycin-resistant cells (clones #1–#10) were analyzed using PCR with specific 
primers (P7–P8) for Cas9v1-Myc (Fig. 6C) and immunoblotting for Cas9v1-Myc (Fig. 6D)and Cas9v2-FLAG 
(Fig. 6E). Lentivirus containing Cas9v1-Myc was successfully removed from the genome in five out of ten (50%) 
puromycin-resistant colonies by NHEJ using the AAV vector #3 (MOI = 0.1), leaving only small pieces of the 
LTR. Although the removal rate among puromycin-resistant cells was not unpropitious, the overall removal 
rate including puromycin-sensitive cells was about 1%. Specific removal of Cas9v1, compared to Cas9v2, was 
confirmed using PCR and immunoblot analyses.
(5) Verification of reconstituted Cas9v2-FLAG function
To verify that the reconstituted Cas9v2-FLAG at the AAVS1 locus was functional for nuclease activity, we exam-
ined whether it could produce DSB at a specific site, with sgRNA targeting the site. We chose the interferon alpha 
and beta-receptor subunit 1 (IFNAR1) gene as  target24,25. The AAV vector #4, targeting exon 1 of IFNAR1 (T4), 
was created by placing a pair of sgRNAs (sg4-1 and sg4-2) with a 7 bp offset, for DSB using Cas9 nickase as well 
as wild-type Cas9 (Supplementary Fig S3). The entire sequence of the AAV vector #4 is shown in Supplemen-
tary Table S1. To select cells containing sgRNA, the hygromycin resistance gene was placed between ITRs, as 
this gene was removed with Cas9v1-Myc in cells expressing the sgRNA3 targeting lentivirus LTR (Fig. 6A,B). 
Cells (Cas9v2-FLAG + sgLenti#10) were then infected with the AAV vector #4, and six hygromycin-resistant 
clones (#1–#6), expressing Cas9v2-FLAG and sgIFNAR1, were obtained. We analyzed the genomic structure of 
IFNAR1 in clones #1 and #3 (Supplementary Fig S4). The cells had heterogeneous insertions and deletions in 
IFNAR1 alleles. Therefore, we confirmed that reconstituted Cas9v2-FLAG is valid for use in editing other genes.
Figure 4.  AAV vector #2 construct used to reconstitute full-length Cas9v2-FLAG in the AAVS1 locus. (A) 
AAV vector #2 was designed to reconstitute full-length Cas9v2 as a double cut donor. T2 is the target site of 
the junction between the 3′-end of 1.9 kb N-terminal Cas9v2 and the 5′-end of P2A (a self-cleaving peptide) 
with PAM. The 2.6 kb C-terminal fragment has a 0.3 kb region overlapping with the 1.9 kb N-terminal Cas9v2 
fragment to reconstitute full-length Cas9v2 by HDR. The T2 sequence was added adjacent to each homology 
arm to cut out the donor DNA from the AAV vector genome. U6, U6 promoter; sg2, the target site T2-specific 
sgRNA2; Bsd, blasticidin resistance gene. (B) Genome structure after integration of the donor by HDR. Primers 
P5–P6 were used to detect the Bsd gene in the AAVS1 locus after HDR. The sequences of AAV vector #2 and 
PCR primers are shown in Supplementary Tables S1 and S3, respectively. *The puromycin-resistant gene is not 
translated to the protein because of the stop codon following the blasticidin resistance gene.
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Introduction of Cas9 nickase in the AAVS1 locus. Although reconstituted Cas9v2-FLAG in the AAVS1 
locus was functional, Cas9 may sometimes cause adverse off-target effects. To reduce the possibility of off-target 
effects in gene editing, we also introduced Cas9v2 nickase with a D10A mutation into the AAVS1  locus22,23. To 
transduce HEK293T cells expressing Cas9v1-Myc (clone #2), we used the 1.7 kb N-terminal of Cas9v2, with a 
D10A mutation (AAV vector #5 in Supplementary Fig S5), instead of the AAV vector #1. Three out of ten puro-
mycin-resistant clones (#1–#10) (30%) possessed the N-terminal Cas9v2 nickase, and the immunoblot analyses 
of independent two clones (Cas9v1-Myc #2 + Cas9v2nickase-NT#7 and #9) are shown in Supplementary Fig S6.
To reconstitute full-length Cas9v2-FLAG nickase, we used the same AAV vector #2 as in Fig. 4 to transduce 
cells expressing both Cas9v1 and the mutated 1.9 kb N-terminal of Cas9v2 (nickase-NT clone #9) (Supplementary 
Fig S7). All 10 cell lines resistant to blasticidin (#1–#10) (100%) expressed both Cas9v1-Myc and full-length 
Cas9v2nickase-FLAG. Immunoblot analyses of independent two clones (Cas9v1-Myc #2 + Cas9v2nickase (full)-
FLAG#3 and #4) are shown in Supplementary Fig S6. The sequence of full-length Cas9v2nickase-FLAG #3, 
including the AAVS1 integration site, was confirmed via Sanger sequencing (Supplementary Table S2).
Finally, we removed the lentiviral vector, containing Cas9v1-Myc, from the genome (full-length Cas9v2nick-
ase-FLAG #3) using the same AAV vector #3 as in Fig. 6. Lentivirus containing Cas9v1-Myc was removed 
from the genome in 3 out of 10 clones (30%), and immunoblot analyses of two clones (Cas9v2nickase (full)-
FLAG#3 + sgLenti#4 and #5) are shown in Supplementary Fig S6.
Introduction of dead Cas9 (dCas9) into the AAVS1 locus. The CRISPR/Cas9 system is used not only 
for the knockout or knock-in of specific genes but also for activation of specific gene  transcription26. We recon-
stituted full-length nuclease-free dead Cas9, carrying D10A and N876A mutations, and conjugated to VP64 
Herpes simplex virus transcriptional activator domain (dCas9v2-VP64) in the AAVS1 locus by transducing 
HEK293T cells expressing both Cas9v1 and D10A-mutated Cas9v2 nickase-NT#9 with the AAV vector #6 (Sup-
plementary Fig S8). All 10 blasticidin-resistant cell lines (100%) expressed the reconstituted full-length dCas9v2-
VP64 as well as Cas9v1-Myc. Immunoblot analyses of two independent clones (Cas9v1-Myc #2 + dCas9v2 (full)-
Figure 5.  PCR and immunoblot to confirm the reconstitution of full-length Cas9v2-FLAG in AAVS1 locus. 
(A) PCR analysis of genomic DNA prepared from the HEK293T-Cas9v1-Myc + Cas9v2-NT #4 cells and the 
HEK293T-Cas9v1-Myc cells expressing full-length Cas9v2-FLAG (+ v2-CT-FLAG #1–#9), after AAV vector 
#2 infection and blasticidin selection. The DNA was amplified by primers P5–P6 and the 1.2 kb PCR products 
indicating the integration of donor elements (Bsd gene) were detected in all clones. (B–D) Lysates obtained 
from the cells used in (A) were analyzed by immunoblot with an antibody against Cas9 that recognizes both 
Cas9s, after 6% SDS-PAGE. The 70-kDa band indicates the 1.9 kb N-terminal Cas9v2 (B). The 160-kDa band 
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VP64 #1 and #2) are shown in Supplementary Fig S6. The sequence of full-length dCas9v2-VP64 #1, including 
the AAVS1 integration site, was confirmed via Sanger sequencing (Supplementary Table S2).
Then, we removed the lentiviral vector, containing Cas9v1-Myc, from cells expressing the full-length dCas9v2-
VP64 #1, using the same AAV vector #3 as in Fig. 6. Lentivirus containing Cas9v1-Myc was removed from 
the genome in four out of 10 clones (40%), and immunoblot analyses of clones #1 and #2 (dCas9v2 (full)-
VP64#1 + sgLenti #1 and #2) are shown in Supplementary Fig S6. Considering that reconstituted full-length 
dCas9v2-VP64 has no nuclease activity, we assume that the remaining Cas9v1-Myc protein, transcribed and 
translated from the Cas9v1-Myc gene before gene removal, worked to remove the lentivirus containing the 
Cas9v1-Myc gene itself. To confirm the ability of dCas9v2-VP64 to activate a specific promoter, we examined 
whether the modified sgRNA with bacteriophage coat protein MS2-binding RNA aptamers, targeting the IFNβ 
gene promoter site and MS2–P65 (NF-κB trans-activating subunit)-HSF1 (human heat shock factor 1) can 
activate IFNβ transcription (Supplementary Fig S9). The expression level of IFNβ transcription was monitored 
using ISRE-Luciferase activity via IFNAR, after transducing the indicated plasmids to express MS2-sgRNA and 
MS2–P65-HSF1, with an ISRE-Luc reporter plasmid. ISRE-Luciferase activity was significantly activated by IFNβ 
targeting (12.8- and 19.0-fold, respectively, compared to the control in clones #1 and #2, respectively); therefore, 
dCas9v2-VP64 effectively activates other genes.
Reducing off-target effects using lentiviral Cas9 nickase. The use of lentiviral Cas9 at the first step 
of the basic procedure stated above has potential off-target effects as well as a genetic risk due to its genomic 
integration. To reduce possible off-target effects caused by the lentiviral Cas9v1, during reconstitution of Cas9v2 
nickase or dCas9v2-VP64 in the AAVS1 locus, we used lentiviral Cas9 nickase instead of wild-type Cas9v1 at 
the first step of the basic procedure (Fig. 7). As shown in Supplementary Fig S10A,B, Cas9 (Nick)-Myc was con-
structed by replacing the N-terminal of Cas9v1 with Cas9v2 nickase. This was performed at the unique BspHI 
restriction enzyme site, in order to differentiate the Cas9v2-FLAG and dCas9v2-VP64 integrated at the AAVS1 
locus, from randomly integrated lentiviral Cas9(Myc)-Myc in the host genome. Cas9 (Nick)-Myc expression 
Figure 6.  AAV vector #3 construct targeting the genome integrated lentivirus long terminal repeat (LTR). 
(A,B) AAV vector #3 targeting the LTR of the lentiviral vector (T3) was created by placing a pair of sgRNAs 
(sg3-1 and sg3-2) with 16 bp offset for DSB (double-strand break) by Cas9 nickase as well as wild-type Cas9 
and placing a puromycin resistance gene between the ITRs. Primers P7–P8 for Cas9v1 are used to examine 
whether the lentivirus containing Cas9v1-Myc is removed by NHEJ with AAV vector #3 infection (B) The 
sgRNA and PCR primer sequences are shown in Supplementary Tables S1 and S3, respectively. (C–E) PCR 
analysis of genomic DNA prepared from the HEK293T-Cas9v1-Myc + full-length Cas9v2-FLAG #7 cells, and 
the HEK293T-Cas9v1-Myc + Cas9v2-FLAG cells (sgLenti #1–#10) expressing sgRNA3 targeting the lentivirus 
LTR, after AAV #3 vector infection and puromycin selection. The DNA was amplified using primers P7–P8 (for 
Cas9v1) (C). The lysates from the cells that had no 1.2 kb PCR products in (C) were analyzed by immunoblot for 
Cas9v1-Myc against Myc-tag (D) and Cas9v2-FLAG with an antibody against FLAG-tag (E).
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was confirmed by immunoblotting after hygromycin selection (Supplementary Fig S10C). Fortunately, there 
were possible Cas9 nickase cleavage sites at both the AAVS1 integration site and at the junction between the 
N-terminal of Cas9v2 and P2A (Supplementary Figs S11 and S12). To introduce the N-terminal Cas9v2 nickase 
with a D10A mutation into the AAVS1 locus, we constructed the AAV vector #7 by adding another sgRNA 
(sg7) to the AAV vector #5, for a DNA DSB via Cas9(Nick) (Supplementary Fig S11). To provide a double-cut 
donor, target sequences (T1) were also replaced with T7/1. The exact sequence of the AAV vector #7 is shown in 
Supplementary Table S1. The AAV vectors # 8 (Supplementary Fig S12) and #9 (Supplementary Fig S13) were 
constructed and used to reconstitute full-length Cas9v2 nickase-FLAG and dCas9v2-VP64, respectively. These 
sequences are listed in Supplementary Table S1.
Sequential infection with AAV vectors without drug selection. Genome restructuring commences 
soon after the introduction of sgRNA and donor dsDNA into 293  T-Cas9 (Nick)-Myc#2 cells. It suggested 
that Cas9v2 reconstitution from two fragments in the AAVS1 locus could be accomplished through sequential 
transductions with two AAV vectors within a short interval (24–36  h) and without drug selection between 
transductions. Following the method outlined in Fig. 8A, the full-length Cas9v2 nickase-FLAG was success-
fully reconstituted through sequential infections of the AAV vectors #7 and #8, within a short 36 h interval 
between transductions, and subsequent blasticidin selection (Fig. 9). Immunological and PCR analyses showed 
that full-length Cas9v2 nickase-FLAG was present at the AAVS1 locus in 83% (5/6) of blasticidin-resistant cells. 
Although all clones expressed the full-length Cas9v2 nickase-FLAG protein (Fig. 9C), clone #6 may carry a 
deletion in the 3′ region of the AAVS1 integration site including the puromycin gene (Fig. 9B). We also analyzed 
lentiviral Cas9 (Nick)-Myc. Unexpectedly, lentiviral Cas9 (Nick)-Myc proteins were not detected in clones #1, 
#2, and #3 (Fig. 9D). Considering that the Cas9 (Nick)-Myc genes were present in the genome of all the clones 
(Supplementary Fig S14), the sequential transductions to reconstitute Cas9v2 nickase-FLAG did not affect the 
lentiviral Cas9 (Nick)-Myc genome structure. Following the same procedure, dCas9v2-VP64 was also recon-
stituted through sequential transductions of the AAV vectors #7 and #9, within a short 36 h interval between 
transductions, and subsequent blasticidin selection (Fig. 8B). As shown in Fig. 10, full-length dCas9v2-VP64 
was reconstituted successfully at the AAVS1 locus in all six clones (100%), although clone #4 was found to have 
a deletion around the right homology arm (Supplementary Fig S15B). Likewise, the lentiviral Cas9 (Nick)-Myc 
proteins were not detected in clones #1, #3, and #6 (Fig. 10D). All the clones had Cas9 (Nick)-Myc genes in 
their genome (Supplementary Fig S14). The overall transduction efficiency of these sequential transductions was 
Figure 7.  Schematic diagram of the four-step strategy using Lentiviral Cas9 (Nick)-Myc. (1) To reduce possible 
off-target effects, lentiviral Myc-tagged Cas9 nickase, termed Cas9 (Nick)-Myc (Supplementary Fig S10), was 
used in the first step. (2) AAV#7 (Supplementary Fig S11) was used to introduce DSB at the AAVS1 site via Cas9 
(Nick)-Myc nickase. (3) AAV#8 (Supplementary Fig S12) was used to reconstitute the full-length 4.2 kb Cas9v2 
nickase-FLAG. If AAV#9 (Supplementary Fig S13) was used instead of AAV#8, dead Cas9 (v2)-VP64 was 
produced, as shown in brackets. (4) Randomly integrated lentivirus, containing Cas9 (Nick)-Myc, was removed 
by AAV vector #3, with sgRNA3 targeting the long terminal repeat (LTR) of the lentivirus vector. sgRNAs 
targeting AAVS1, the 3′-end of the 1.9 kb Cas9v1 N-terminal fragment, and the LTR of the lentivirus are shown 
as sg7/1, sg8/2, and sg3, respectively.
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approximately 3%, as an average of 15 colonies appeared from the initial 500 HEK293T-Cas9 (Nick)-Myc cells 
in both experiments.
It is difficult to use drug selection markers in vivo. To consider the possibility of in vivo use of this method, 
we measured the transduction efficiency at each step. For the first step of lentiviral introduction of Cas9 in the 
genome, we obtained Cas9 (Nick)-Myc-expressing colonies (1/10 and 1/10) in two independent experiments 
(10%) using the lentivirus containing Cas9 (Nick)-Myc (MOI = 2) without drug selection, as shown in Supple-
mentary Fig S16. In the second step, however, we could not obtain any colonies expressing NT1.7k-Cas9v2 out of 
30 colonies using a high concentration of AAV vector #1 (MOI = 20) without drug selection. In the third step, the 
cells containing the 1.9 kb N-terminal nickase fragment at the AAVS1 locus (Cas9v1-Myc + Cas9v2nickase-NT#9) 
were infected with high concentrations of the AAV vectors #2 or #6 (MOI = 20, each) without drug selection. The 
reconstitution rates of full-length Cas9v2nickase-FLAG and full-length dCas9v2-VP64 were 3/6 (50%) and 3/6 
(50%), respectively. Supplementary Fig S17 shows the reconstituted full-length Cas9v2 nickase-FLAG with AAV 
#2 vector. In the fourth step, the removal rate of lentiviral Cas9v1 from the Cas9v1-Myc + Cas9v2(full)-FLAG#7 
cells, without drug selection, was approximately 50% (#1: 3/6, #2: 5/9, and #3: 4/10 in the three independent 
experiments) using a high concentration of the AAV vector #3 (MOI = 20). Supplementary Fig S18 shows the data 
of #3 experiment without drug selection. We could not determine the transduction efficiency of the N-terminal 
Cas9v2 nickase fragment in the second step, as stated above. Considering that the induction efficiency of the 
sequential second and third infections was 3% and that the induction rate of the third step was 50%, the second 
step induction rate was simply expected to be 6%. If the third step induction rate is 100%, the second step induc-
tion rate is calculated to be 3%. However, sequential transductions might have a favorable effect on the second 
and third inductions. Therefore, we estimate the second step induction will be 3–6% without drug selection.
Discussion
We proposed an effective method to introduce Cas9 into the AAVS1 locus using viral vectors. Stably expressed 
Cas9, especially Cas9 nickase, in the safe harbor can be used for precise gene editing. Considering that NHEJ, fol-
lowed by DSB, is error-prone, precise genome editing using HDR is required, especially during in vivo  use5–7,20,21. 
Although the first lentiviral induction of Cas9 (Nick)-Myc, using this method, was approximately 10% (MOI = 2), 
without drug selection (Supplementary Fig S16), the lentiviral induction rate could be increased using higher 
titers of virus. While the second induction efficiency of Cas9v2 N-terminal fragments was poor (speculated to 
be 3–6%), the induction rate of Cas9v2 C-terminal parts (the third step), was satisfactory without drug selection 
Figure 8.  Sequential transduction procedure using AAV vectors. (A) According to the scheme shown in figure, 
293 T-Cas9(Nick)-Myc cells (500/well) plated in a 24-well plate were incubated with 10,000 transduction units 
of AAV#7, which provided sgRNA targeting the AAVS1 site, and 1.9 kb Cas9v2 nickase N-terminal fragments 
(Supplementary Fig S11), for 36 h. Following medium aspiration, cells were sequentially incubated with 10,000 
transduction units of AAV#8 (Supplementary Fig S12), for 24 h, to reconstitute full-length Cas9 (v2) nickase-
FLAG. Cells were transferred to a 6-well plate, with blasticidin added two days after transfer. Colonies were 
collected after 10 days in the presence of blasticidin and analyzed using PCR and immunoblot. (B) 293 T-Cas9 
(Nick)-Myc cells (500/well) were sequentially incubated with AAV#7 and AAV#9 (Supplementary Fig S13) to 
reconstitute full-length dCas9 (v2)-VP64. Blasticidin-resistant cells were analyzed using PCR and immunoblot.
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(about 50%) (Supplementary Fig S17). Sequential transfection data showed a Cas9 reconstitution rate of 3% from 
Cas9 (Nick)-Myc-expressing cells without drug selection (Figs. 8, 9, 10). Further, the overall Cas9 reconstitution 
rate was 0.3% of 293 T cells, given a lentiviral Cas9 (Nick)-Myc induction rate of 10%. The Cas9 (Nick)-Myc 
induction rate may be increased through higher concentrations of lentivirus (more than MOI = 2). Therefore, it 
is important to improve the efficacy of limiting N-terminal Cas9v2 induction in the second step. We speculate 
that the insertion of N-terminal Cas9v2 into one allele induces a structural change that may allow easier access 
to the target site, for the donor C-terminal Cas9v2, resulting in the high transduction efficiency of the third 
step. Some reagents and molecules have been reported to enhance  HDR7,27–29. For example, CtIP-fused Cas9 
was used to bring essential components to the Cas9-mediated DSB site, while monoavidin-fused Cas9 recruits 
biotinylated donor DNA to Cas9, thus enabling  HDR28–30. Combining some of these methods with our system 
may further improve HDR rates.
The fourth step of our procedure focused on removing lentivirus containing Cas9v1-Myc; the removal rate 
was approximately 50%, without drug selection (Supplementary Fig S18). In addition, stable expression of 
Cas9v2-FLAG at the AAVS1 locus enables multiple attempts to remove lentivirus using the same or different 
sgRNA targeting LTR; thus, it was possible to repeat until all lentiviruses were  removed16,17. As for the genetic 
risk, as each recombinant lentivirus is usually integrated into only one  allele31,32, the destruction of a single tumor 
suppressor gene is not likely to be pathogenic. However, accidental activation of oncogenes, genes, or miRNAs 
critical for cell cycle or proliferation, via lentivirus insertion cannot be ruled out.
Alternative approaches to reduce the genetic risk associated with lentiviral integration into the genome may 
include transient expression of Cas9v1 using non-integrating lentiviral  vector13,14. AAV vectors that express 
SaCas9 (small enough for AAV packaging)10, or split-Cas9 (N- and C-terminal parts are combined after transla-
tion)11,12 may be sufficient for Cas9v2 reconstitution at the AAVS1 locus. Figures 8, 9 and 10 show that integration 
of combined Cas9v2 nickase-FLAG or dCas9v2-VP64, at the AAVS1 locus, was completed within a couple of days 
via sequential transductions of the two AAV vectors (containing NT- and CT-Cas9v2 parts). Transient expres-
sion of Cas9(Nick)-Myc via non-integrating lentiviral vector, or SaCas9 via the AAV vector, appeared sufficient 
for the reaction as shown in Supplementary Fig S19. Consequently, the fourth step to remove the integrated 
lentivirus containing Cas9v1 could be omitted.
As for targeting cells for the integration of lentivirus carrying Cas9v1, used in the first step, many human cell 
types are susceptible to infection by the vesicular stomatitis virus G protein (VSVG)-pseudotyped recombinant 
 lentiviruses33. However, the broad VSVG tropism can be controlled through the insertion of a 49-amino-acid 
Figure 9.  PCR and immunoblot analysis to confirm the reconstitution of full-length Cas9v2nickase-FLAG in 
the AAVS1 locus. (A,B) PCR analysis of genomic DNA prepared from HEK293T, HEK293T-Cas9(Nick)-Myc, 
and HEK293T-Cas9(Nick)-Myc + v2n-NT + CT-FLAG #1–#6 cells, after sequential infections of AAV vectors #7 
and #8, as in Fig. 8A. v2n-NT, 1.9 kb Cas9v2 nickase-NT; CT-FLAG, 2.3 kb Cas9v2-CT-FLAG. Primers P1–P3 
(Cas9v2), and P4–P2 (Puro), were used to examine the integration efficiency of the reconstituted full-length 
Cas9v2nickase-FLAG into the AAVS1 locus at the 5′- and 3′-regions. (C–E) Lysates obtained from the same 
cells used for the PCR analysis were analyzed using immunoblot, with the antibodies indicated. Arrows indicate 




Scientific Reports |        (2020) 10:21474  | https://doi.org/10.1038/s41598-020-78450-8
www.nature.com/scientificreports/
peptide (echistatin), or a single-chain variable fragment (scFv) at the N-terminal, or some specific VSVG sites, 
thus directing it to cells expressing integrin αVβ3 or the molecule against  scFv34,35. If a lentivirus carrying Cas9v1 
is pseudotyped with the modified VSVG, specific cells could be targeted to express Cas9v1. That enables the 
subsequent Cas9v2 integration at the AAVS1 locus only in the targeted cells.
Thus, the merits of our method over existing single-vector technologies for gene therapy are as follows: (1) 
stable and robust Cas9v2 expression in the AAVS1 locus facilitates precise gene editing when using HDR. (2) 
The availability of various types of modified Cas9 that exceed the AAV vector packaging capacity, including 
Cas9 nickase, to minimize off-target effects (Supplementary Fig S19). (3) Using non-integrating lentiviral vec-
tor to express Cas9 nickase transiently, or AAV-SaCas9 for the first step, could minimize genetic risk and save 
the fourth step (Supplementary Fig S19). (4) Targeting cells for integration could be controlled by pseudotyped 
with modified VSVG. (5) The high lentivirus removal rate (Supplementary Fig S18); sgRNA targeting LTR could 
be used to remove the lentivirus if illegitimate integration caused abnormal cell growth. This not only provides 
safety when using lentivirus for gene therapy but may also be used for the removal of human immunodeficiency 
virus (HIV), human T-cell leukemia virus type 1 (HTLV1), integrated in acquired immune deficiency syndrome 
(AIDS) or adult T-cell leukemia/lymphoma.
In order to apply our method in vivo, we have to overcome the overall low reconstitution rate of Cas9 in 
the AAVS1 locus without drug selections as stated above. In addition, the presence of neutralizing antibodies 
against wild-type AAVs in the host body deters the therapeutic use of AAV  vectors8. There are concerns that 
the host immune reaction to the capsid of the AAV #1 may prevent the subsequent transduction of the AAV 
#2 and #3, and that the stable and robust expression of foreign protein Cas9 (not only full-length Cas9 but also 
N-terminal Cas9 that was not successfully reconstituted) may induce unwanted immune  reactions36. Targeting 
specific genes such as the STING-STAT6 axis, however, might prevent these unwanted immune  responses37–39. 
Sequential transductions of AAVs within short intervals, as shown in Figs. 8, 9 and 10, might conclude the gene 
therapy process before the induction of neutral antibodies against previous AAVs. However, we must take into 
account the fatal risk of using high concentrations of AAV vectors in vivo40.
Methods
Cell lines and cell culture. Human embryonic kidney HEK293T and LENTI-X 293 T cells (Takara Bio Inc. 
#632180) were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum. To 
generate stable cell lines, we used 0.3 mg/mL hygromycin B (Wako #084-07681), 2.5 μg/mL puromycin (Nacalai 
#14861-71), or 32 μg/mL blasticidin S (Wako #026-18711) for at least two weeks unless otherwise described.
Figure 10.  PCR and immunoblot analysis to confirm the reconstitution of full-length dCas9v2-VP64 in the 
AAVS1 locus. (A,B) PCR analysis of genomic DNA prepared from HEK293T, HEK293T-Cas9(Nick)-Myc, and 
HEK293T-Cas9(Nick)-Myc + v2n-NT + dCT-VP64 #1–#6 cells, after sequential infections of AAV vectors #7 
and #9, as in Fig. 8B. v2n-NT, 1.9 kb Cas9v2 nickase-NT; dCT-VP64, 2.3 kb dCas9v2-CT-VP64. Primers P1–P3 
(Cas9v2), and P4–P2 (Puro), were used to examine the integration efficiency of the reconstituted full-length 
dCas9v2-VP64 into the AAVS1 locus at the 5′- and 3′-regions. (C–E) Lysates obtained from the same cells 
used for the PCR analysis were analyzed using immunoblot, with the antibodies indicated. Arrows indicate 
reconstituted full-length dCas9v2-VP64 (170 kDa), lentiviral Cas9 (Nick)-Myc (160 kDa), and β-actin (45 kDa).
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Virus constructs. The SIN-type lentiviral vector pLVSIN-EF1a Hyg (#6185) and AAV2 serotype vector 
pAAV-CMV (#6230) were purchased from Takara Bio Inc. pCas-Guide (#GE10002) was purchased from Ori-
Gene Tech. Inc. lentiCRISPR v2 was a gift from Feng Zhang (Addgene plasmid #52961; http://n2t.net/addge 
ne:52961 )19. lentiSAMv2 was also a gift from Feng Zhang (Addgene plasmid #75112; http://n2t.net/addge 
ne:75112 )26. The lentivirus pLVSIN was modified to express Cas9v1 (SpCas9 from pCas-Guide)-Myc and hygro-
mycin resistance gene (Hygro) connected to the self-cleaving peptide T2A under a CMV promoter. Cas9(Nick)-
Myc was constructed by replacing N-terminal Cas9v1 with Cas9v2 nickase at the unique BspHI restriction 
enzyme site, as shown in Supplementary Fig S10. After infecting 293 T cells with a series of viral solution dilu-
tions, the lentiviral titer (transduction unit/ml) was determined from the number of colonies that survived for 
ten days in the presence of 0.3 mg/mL hygromycin B.
An AAV vector #1 targeting the AAVS1 locus (T1) was constructed by placing the AAVS1-specific sgRNA1 
(sg1) and several elements by the AAVS1-driven transcript flanking the homology arms between the ITRs. 
These elements are SA-T2A (a self-cleaving peptide), 1.9 kb N-terminal Cas9v2 fragment T2A (a self-cleaving 
peptide)-puromycin resistance gene, and a polyadenylation (pA) sequence. The targeting sequences (T1) were 
added adjacent to the homology arms to enable HDR by creating a double-cut donor. The sequences are shown 
in Supplementary Table S1.
The AAV vector #2 sequence is also listed in Supplementary Table S1. sgRNA2 (sg2) targets the junction (T2) 
between the 3′-end of 1.9 kb N-terminal Cas9v2 and the 5′-end of P2A (a self-cleaving peptide). To reconstitute 
the full-length of Cas9v2, we overlapped the 0.3 kb region between the 1.9 kb N-terminal and 2.3 kb C-terminal 
region of Cas9v2. The 0.3 kb overlap works as the left arm in HDR. As for the right arm, the P2A and N-terminal 
0.3 kb fragment of puromycin flank the T2 targeting sequence and the ITR to provide a double-cut donor.
The AAV vector #3 targets the LTR of the lentiviral vector by a pair of sgRNAs (sg3-1 and sg3-2) with a 16 bp 
offset for DSB by nickase Cas9 and wild-type Cas9, as shown in Supplementary Table S1. The AAV vector #4 
targeting exon1 of IFNAR1 (T4) was constructed by placing a pair of sgRNAs (sg4-1 and sg4-2) with a 7 bp offset 
for DSB by nickase Cas9 and wild-type Cas9, and placing the hygromycin-resistance gene between the ITRs. The 
AAV #5 was the same as AAV #1 except for the D10A mutation (GAC → GCC) in the 1.7 kb N-terminal Cas9v2, 
and AAV #6 was the same as AAV #2 except for the N863A mutation (AAC → GCC) in the 2.3 kb C-terminal 
Cas9v2 with VP64 transcriptional activator. AAV vector #7 was constructed by adding another sgRNA (sg7) to 
the AAV vector #5 and replacing the T1 target sequence with T7/1, as shown in Supplementary Fig S11. The AAV 
vectors #8 (Supplementary Fig S12) and #9 (Supplementary Fig S13) were also constructed by adding another 
sgRNA (sg8) to AAV vectors #2 and #6, respectively, and replacing the T2 target sequence with T8/2. The exact 
sequences of AAV vectors #7, #8, and #9 are listed in Supplementary Table S1.
After infecting 293 T cells with a series of diluted viral solutions, the AAV viral titer (transduction unit/ml) 
of vectors #3 and #4 was directly determined via the number of colonies that survived for ten days in the pres-
ence of 2.5 μg/mL puromycin or 0.3 mg/mL hygromycin B. The bioassay is not suitable for the AAV vectors #1, 
#2, #5, #6, #7, #8, or #9, because the drug resistance markers are activated only when they are integrated into 
the designated sites. So, we used real-time PCR, with specific primers (P11-P12 in Supplementary Table S3) to 
first measure the physical amount of puromycin gene in each virus solution, after residual DNA fragments were 
removed from the virus solution by incubation with an anion-exchange resin in 0.3 M NaCl, and 20 mM Tris, 
pH7.0 (Q-FAST FLOW, Pharmacia). Next, the physical amount of puromycin gene was used to estimate the 
biological viral titer of each virus solution (transduction units/mL), referring to the relationship between the 
physical amount of puromycin gene of the AAV vector #3 virus solution determined by real-time PCR and the 
biological viral titer of AAV #3 virus solution.
Cell transduction. The SIN-type lentivirus vector was co-transfected with ViraPower lentiviral packaging 
mix (Invitrogen #K497500) into Lenti-X 293 T cells (Takara #632180) using Lipofectamine 2000 transfection 
reagent (Thermo Fisher Scientific #11668027). After 3 days, the supernatant containing recombinant virus par-
ticles was concentrated using Lenti-X concentrator (Takara Bio #631231) and used for cell infection (MOI = 0.1–
2) in the presence of 8 μg/mL Polybrene (Nakalai #12996-81). Each AAV vector was co-transfected with pHelper 
and pRC-mi342 vectors (Takara #6234 for AAV2) into HEK293T cells using the Lipofectamine 2000 transfec-
tion reagent. After three days, the recombinant AAV particles were extracted with AAVpro Extraction Solution 
(Takara #6235) according to the manufacturer’s instructions and used for cell transduction.
For sequential transduction, 293 T-Cas9 (Nick)-Myc cells (500/well) plated in a 24-well plate were incubated 
with 10,000 transduction units of AAV #7, which provided sgRNA targeting the AAVS1 site, along with 1.9 kb 
Cas9v2 nickase N-terminal fragments, for 36 h. Following medium aspiration, cells were sequentially incubated 
with 10,000 transduction units of AAV #8 or AAV #9 for 24 h, to reconstitute the full-length Cas9(v2) nickase-
FLAG or dCas9(v2)-VP64, respectively. Cells were transferred to a 6-well plate, and blasticidin was added two 
days after transfer. Colonies were collected after 10 days in the presence of 32 μg/mL blasticidin S and analyzed 
using PCR and immunoblot.
Genomic DNA isolation and PCR. Genomic DNA was extracted from semi-confluent cells plated in 
24-well plates. After 1% Triton X-100-mediated extraction of cytosolic content, samples were treated with 
180 μg/mL proteinase K (Nacalai #15679-06) for 24 h in a buffer containing 0.5% SDS. Samples were treated with 
phenol/chloroform/isoamyl alcohol (25:24:1), precipitated with ethanol, and dissolved in TE after 70% ethanol 
wash. Genomic DNA (100 ng each) was subjected to PCR using the specific primers listed in Supplementary 
Table S3, and KOD-FX-NEO DNA Polymerase (TOYOBO #KFX-201) on a LightCycler 1.5 (ABI). The general 
reaction conditions were 94 °C for 2 min followed by 35 cycles of 10 s of denaturation at 98 °C, 10 s of annealing 
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at 62 °C, and 1 min of extension at 68 °C unless otherwise  described41. The PCR products were separated on a 1% 
agarose gel. DNA fragments were purified, and the sequences were directly determined by Sanger sequencing.
Immunoblot analysis. Cell lysates were extracted from semi-confluent cells plated in 24-well plates using 
GLO lysis buffer (Promega #E2661). The protein concentration of each cell lysate was measured with BCA 
(bicinchoninic acid) protein assay, and the 10 μg aliquot was separated by 5–12.5% SDS-PAGE and transferred 
to poly vinylidene di-fluoride (PVDF) membranes. Specific proteins were detected using an anti-Cas9 polyclonal 
antibody (Takara Bio #632607), anti-Myc-tag (9B11) mouse monoclonal antibody (Cell Signaling Technology 
#2276S), anti-FLAG M2 monoclonal antibody (Sigma-Aldrich #F1804), or anti-β-actin mouse monoclonal anti-
body (Santa-Cruz #SC-47778) and were used at 1:500–3000 dilution. They were visualized with HRP-conjugated 
anti-rabbit or anti-mouse IgG antibody and ECL  reagent41.
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